2026-11-092026-11-09https://scholars.csmu.edu.tw/handle/123456789/38584Brain tumors are the third leading cause of cancer-related death in those aged 15-34 years old. In particular, glioblastoma multiforme (GBM) and malignant gliomas present the lowest one-year survival rates. Current anti-tumor drugs are not effective against GBM. The traditional Chinese herbal medicine are using over thousand years, and have a lower or event none side effects in clinical treatment. There are several Traditional Chinese Medicine (TCM) using for cook and clinical treatment. The purpose of this study is to investigate the anti-cancer effects of extracts of TCM in tumors by bioactivity-guided fraction and purification. There are five TCMs, such as Ginseng Radix, Crataegi Fructus, Rehmanniae Radix, Glycyrrhizae Radix and Zingiberis rhizoma, that will extract and exam in this stdudy. The experimental design of this study as following: In vitro, tumor cells will treat with crude extracts, and determine the cytotocixity, changes in distributions of cell cycle, and apoptosis. In vivo, human and rat tumor cells will inject by s.c. or i.c. and treat with crude extracts. Effects on tumor growth will determine by tumor volume, MRI, survival rate and histology analysis. Finally, the mechanism of crude extracts induction will be find out and toward to development an anticancer agent.腦瘤是佔癌症相關而引起15-34 歲青壯年死亡之第三位，此外惡性腦 瘤(Glioblastoma multiforme; GBM)之病人存時間大多少於一年。目前臨床 用來治療腦腫瘤之化療藥物，其抗癌效果皆不如預期佳。在東方醫學中， 中醫藥已被使用有幾千年之歷史，天然的中藥藥材於正常使用下引起的副 作用是極輕微、甚至無副作用的，且有部分中藥早已在日常生活中被大量 使用成為食品中藥。本實驗之目的為: 以生物活性引導篩藥之方式，從食 品中藥中開發出一種能抑制或毒殺惡性腫瘤生長之藥物，但此藥物必須是 生理可接受其毒性之藥物。此計畫分年三年進行，研究之實驗設計為：選 用人參、山楂、生地、乾薑及甘草等五種之食品中藥進行分離萃取，將所 萃取之粗萃物分別進行下列實驗。於體外測試(in vitro study)，以粗萃物分 別處理多株之腦腫瘤之細胞株，觀察並紀錄細胞形態、細胞毒性、細胞生 長情形、細胞週期之分佈、細胞凋亡及細胞凋亡相關分子之表現情形。於 體內測試(in vivo study)，建立人類惡性腫瘤及同源性大鼠惡性腦腫瘤，其 皮下及原位腦腫瘤之化療模式，分別以粗萃物治療，觀察並紀錄腫瘤生長 情形、腫瘤體積大小、動物存活率並組織病理分析，最末分析粗萃物於體 外及體內引起之抑癌機制，進而研發成新一種抗腫瘤之藥物。惡性腫瘤中藥抗癌藥物細胞週期細胞凋亡malignant tumorTraditional Chinese Medicine (TCM)anticancerdrugCell cycleApoptosisProject